Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial – AstraZeneca September 22, 2023
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups – Novartis June 2, 2023
Baltimore Ravens gun for ‘meaningful’ rushing record in lieu of ending game with QB kneel October 4, 2021October 4, 2021
Democrats vow ‘meaningful’ relief for state and local tax deduction September 15, 2021September 15, 2021
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 March 29, 2021